表5 心肌动作电位试验中的重要参数项目
可参考的文献 1.
De Clerck F et al, In vivo measurement of QT
prolongation, dispersion and arrhythmogenesis: application to the preclinical
cardiovascular safety pharmacology of a new chemical entity, FundamClinPharmacol,
2002;16:125-40. 2.
Sanguinetti MC, Mitcheson JS, Predicting
drug-hERG channel interactions that cause acquired long QT syndrome, Trends
Pharmacol Sci,2005;26: 119-24. 3.
Lawrence CL et al, Nonclinical proarrhythmia
models: Predicting Torsades de Pointes, J PharmacolToxicol Methods,2005; 52:
46–59 4.
Guth BD, Preclinical cardiovascular risk
assessment in modern drug development, ToxicolSci, 2007; 97, 4–20. 5.
KettenhofenR,Bohlen H, Preclinical assessment
of cardiac toxicity, Drug Discov Today, 2008;13:702-7. 6.
Sugiyama A Sensitive and reliable proarrhythmia
in vivo animal models for predicting drug-induced torsades depointes in
patients with remodelled hearts, Br J Pharmacol, 2008;154:1528-37. 7.
Valentin JP, Hammond T Safety and secondary
pharmacology: Successes, threats, challenges and opportunities, JpharmacolToxicol
Methods,2008;58: 77–87. 8.
Valentin JP etal A framework to assess the
translation of safety pharmacology data to humans, J
PharmacolToxicolMethods,2009;60:152–58 9.
Amanfu,RK , Saucerman, JJ, Cardiac models in
drug discovery and development: a review, Crit Rev Biomed Eng,2011;39:379-95. |
